Get the Stockscreener App
6.36
7.56%
-0.52
After Hours:
6.31
-0.05
-0.79%
Kyverna Therapeutics Inc stock is traded at $6.36, with a volume of 413.99K.
It is down -7.56% in the last 24 hours and up +15.22% over the past month.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
See More
Previous Close:
$6.88
Open:
$6.67
24h Volume:
413.99K
Relative Volume:
0.74
Market Cap:
$275.04M
Revenue:
-
Net Income/Loss:
$-110.66M
P/E Ratio:
-2.0541
EPS:
-3.0963
Net Cash Flow:
$-97.76M
1W Performance:
-16.43%
1M Performance:
+15.22%
6M Performance:
+178.95%
1Y Performance:
+23.26%
1-Day Range:
$6.30
$6.93
1-Week Range:
$6.30
$8.11
52-Week Range:
$1.78
$8.4471
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Name
Kyverna Therapeutics Inc
Sector
Industry
Phone
(510) 626-8331
Address
5980 HORTON STREET, EMERYVILLE
Compare KYTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
6.36 | 297.53M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | William Blair | Outperform |
| May-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-10-24 | Initiated | UBS | Buy |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Jul-03-24 | Initiated | H.C. Wainwright | Neutral |
| Mar-04-24 | Initiated | JP Morgan | Overweight |
| Mar-04-24 | Initiated | Leerink Partners | Outperform |
| Mar-04-24 | Initiated | Morgan Stanley | Overweight |
| Mar-04-24 | Initiated | Wells Fargo | Overweight |
View All
Kyverna Therapeutics Inc Stock (KYTX) Latest News
Kyverna secures $150 million loan facility to advance autoimmune therapies By Investing.com - Investing.com Australia
What the charts say about Kyverna Therapeutics Inc. todayJuly 2025 Patterns & Technical Confirmation Trade Alerts - newser.com
Is Kyverna Therapeutics Inc. stock attractive for passive investorsEarnings Trend Report & Daily Growth Stock Tips - newser.com
Why Kyverna Therapeutics Inc. stock remains undervaluedQuarterly Earnings Report & Safe Capital Growth Stock Tips - newser.com
Is Kyverna Therapeutics Inc. stock vulnerable to regulatory risks2025 Growth vs Value & Real-Time Volume Triggers - newser.com
Pattern recognition hints at Kyverna Therapeutics Inc. upside2025 Market Outlook & Verified Short-Term Trading Plans - newser.com
Kyverna secures $150 million loan facility to advance autoimmune therapies - Investing.com
Kyverna Therapeutics Secures $150 Million Loan Facility - TipRanks
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance - The Manila Times
[8-K] Kyverna Therapeutics, Inc. Reports Material Event | KYTX SEC FilingForm 8-K - Stock Titan
Kyverna (Nasdaq: KYTX) secures up to $150M non-dilutive financing maturing 2030 - Stock Titan
Using economic indicators to assess Kyverna Therapeutics Inc. potentialJuly 2025 Catalysts & Weekly Setup with ROI Potential - newser.com
How sentiment analysis helps forecast Kyverna Therapeutics Inc.CEO Change & Safe Capital Preservation Plans - newser.com
Kyverna Therapeutics Reports Positive Phase 2 Trial Results - MSN
Will Kyverna Therapeutics Inc. stock deliver long term returnsMarket Growth Review & Weekly Market Pulse Alerts - newser.com
Combining price and volume data for Kyverna Therapeutics Inc.Weekly Trade Summary & Safe Entry Momentum Tips - newser.com
Can machine learning forecast Kyverna Therapeutics Inc. recoveryTrade Entry Summary & High Accuracy Trade Alerts - newser.com
Is Kyverna Therapeutics Inc. stock a buy before product launchesTrade Analysis Report & Daily Risk Controlled Trade Plans - newser.com
Analysts Conflicted on These Healthcare Names: Kyverna Therapeutics, Inc. (KYTX), Disc Medicine (IRON) and Baxter International (BAX) - The Globe and Mail
Kyverna Therapeutics (KYTX) Price Target Increased by 16.46% to 23.46 - MSN
Kyverna Therapeutics, Inc. (KYTX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Promising Phase 2 Data and Favorable Safety Profile Drive Buy Rating for Kyverna Therapeutics’ KYV-101 - TipRanks
What is HC Wainwright's Estimate for KYTX Q3 Earnings? - MarketBeat
Kyverna Therapeutics Advances in Lupus Nephritis Treatment with KYV-101 CAR T-Cell Therapy - MSN
Kyverna’s CAR T Therapy Sets 'New Efficacy Standard' in Myasthenia Gravis, De-Risking Phase III Trials - BioSpace
Amen at AANEM: Kyverna makes good on MG phase II promise - BioWorld MedTech
Kyverna Therapeutics Reports Positive Phase 2/3 Trial Data - TipRanks
Kyverna Therapeutics stock surges after positive myasthenia gravis trial data By Investing.com - Investing.com Canada
KYTX to host 8:00 a.m. ET call on KYV-101 Phase 2/3 results - Stock Titan
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 - The Manila Times
Kyverna Therapeutics Reports Promising Interim Results from Phase 2 Trial of KYV-101 in Generalized Myasthenia Gravis, Setting a New Clinical Standard - Quiver Quantitative
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study - TradingView
Kyverna Therapeutics announces positive interim phase 2 data from KYSA-6 study of KYV-101 in generalized Myasthenia gravis at AANEM 2025 - MarketScreener
Kyverna KYTX shares Phase 2 interim KYV-101 results in gMG update - Stock Titan
Kyverna (Nasdaq: KYTX): 100% MG-ADL and QMG response in gMG Phase 2; no ICANS - Stock Titan
How strong is Kyverna Therapeutics Inc. stock balance sheet2025 Year in Review & Fast Exit/Entry Strategy Plans - fcp.pa.gov.br
Kyverna Therapeutics Inc Stock (KYTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):